Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies
Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific will describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.
Learning Objectives
- How innovation in upstream technology will deliver process robustness and titer enhancement
- How to optimize and effectively scale up downstream bioprocess workflows in order to capitalize on increased upstream yields
- What is the latest thinking and innovation in developing the analytics needed to improve both the quality and efficiency of viral vector manufacture for gene therapy
- New regulatory paradigm for accelerated cell and gene therapy product development
- Key points of future focus for further investment and collaboration
Speaker Information
Brandon Pence
Vice President and General Manager, Purification and Pharma Analytics
Thermo Fisher Scientific
Brandon Pence serves as VP and General Manager of the Purification and Pharma Analytics business in Salt Lake City, Utah. Brandon Pence has more than 20 years of experience in the life sciences industry leading teams in R&D, product management, marketing and business strategy.
Richard Snyder, PhD
Vice President, Science & Technology, Pharma Services, Viral Vector Services
Thermo Fisher Scientific
Dr. Richard O. Snyder, Ph.D. is the VP for Science and Technology, Pharma Services, Viral Vector Services at Thermo Fisher Scientific. Dr. Snyder has been investigating virus biology, vector development, cGMP vector manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 33 years and was a member of the teams who developed novel viral vector-based human gene therapies.
Kate Torchilin
Vice President and General Manager, Cell Culture and Cell Therapy
Thermo Fisher Scientific
Dr. Kate Torchilin, Ph.D. is VP and General Manager of Cell Culture & Cell Therapy, BioProduction at Thermo Fisher Scientific. Kate previously was responsible for Purification & Pharma Analytics, BioProduction at Thermo Fisher Scientific.
For research use or further manufacturing, not for diagnostic use or direct administration in humans or animals.